Concepedia

Publication | Open Access

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer

DOIFull Paper Access

20

Citations

21

References

2018

Year

Toby A. Eyre, Graham P. Collins, Avinash Gupta, Nicholas Coupe, Semira Sheikh, John A. Whittaker, Lai Mun Wang, Leticia Campo, Elizabeth J. Soilleux, Finn Tysoe,
Cancer

Abstract

The MTD in the current study was found to be 20 mg twice daily. Encouraging and durable activity was observed in patients with Hodgkin lymphoma, T-cell lymphoma, and follicular lymphoma.

References

YearCitations

Page 1